Evangelisches Krankenhaus Witten gGmbH

The medical center is at the forefront of research in venous thromboembolism (VTE) associated with gastrointestinal and genitourinary cancers. The institution is dedicated to exploring innovative treatments that aim to reduce the recurrence of VTE in cancer patients, enhancing their quality of life and treatment outcomes.

• VTE management in cancer patients
• Comparative studies of anticoagulants
• Long-term outcomes of VTE treatments

Through rigorous clinical trials, the center is evaluating the efficacy of novel anticoagulants, such as abelacimab, in comparison to established treatments like dalteparin, aiming to establish new standards in VTE management.

Specializing in the imaging of inflammatory diseases, the center is pioneering the use of advanced PET/CT technology to visualize inflammation in conditions such as giant cell arteritis and rheumatoid arthritis. This research is crucial for improving diagnostic accuracy and monitoring disease progression.

• Advanced imaging techniques
• Inflammation visualization
• Diagnostic innovations in arthritis

The center's work with 89Zr-Dfcrefmirlimab uptake in PET/CT scans is setting new benchmarks in the non-invasive assessment of inflammatory activity, offering potential for earlier and more precise interventions.

Focusing on refractory focal onset epilepsy, the center is conducting cutting-edge research to evaluate the effectiveness and safety of new therapeutic agents. This research is pivotal in providing alternative treatment options for patients who do not respond to conventional therapies.

• Novel epilepsy treatments
• Adjunctive therapy efficacy
• Seizure reduction strategies

By investigating the potential of BHV-7000 as an adjunctive therapy, the center aims to significantly reduce seizure frequency, offering hope to those with limited treatment options.